Repare Therapeutics
$2.65
14
+$0.02+0.76% Tuesday 21:00
Statistics
Day High
2.65
Day Low
2.62
52W High
2.66
52W Low
0.89
Volume
1,167,676
Avg. Volume
1,110,790
Mkt Cap
113.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
3MarExpected
Expected EPS
-0.29
Actual EPS
N/A
Financials
-158.37%Profit Margin
Unprofitable106.95MRevenue
-169.38MNet Income
Analyst Ratings
$3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow RPTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
Editas Medicine
EDIT
Mkt Cap261.32M
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Beam Therapeutics
BEAM
Mkt Cap2.51B
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Fate Therapeutics
FATE
Mkt Cap141.84M
Novartis
NVS
Mkt Cap297.32B
Gilead Sciences
GILD
Mkt Cap173.41B
About
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Show more...
CEO
Dr. Michael Zinda Ph.D.
Employees
129
Country
CA
ISIN
US7602731025
Listings
0 Comments
Share your thoughts
FAQ
What is Repare Therapeutics stock price today?▼
The current price of RPTX is $2.65 USD — it has increased by +0.76% in the past 24 hours. Watch Repare Therapeutics stock price performance more closely on the chart.
What is Repare Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Repare Therapeutics stocks are traded under the ticker RPTX.
Is Repare Therapeutics stock price growing?▼
RPTX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Repare Therapeutics has showed a +178.95% increase.
What is Repare Therapeutics market cap?▼
Today Repare Therapeutics has the market capitalization of 113.91M
What is Repare Therapeutics revenue for the last year?▼
Repare Therapeutics revenue for the last year amounts to 106.95M USD.
What is Repare Therapeutics net income for the last year?▼
RPTX net income for the last year is -169.38M USD.
How many employees does Repare Therapeutics have?▼
As of April 08, 2026, the company has 129 employees.
In which sector is Repare Therapeutics located?▼
Repare Therapeutics operates in the Health Care sector.
When did Repare Therapeutics complete a stock split?▼
Repare Therapeutics has not had any recent stock splits.
Where is Repare Therapeutics headquartered?▼
Repare Therapeutics is headquartered in Montreal, CA.